Compare VanEck Junior Gold Miners (GDXJ) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs Eli Lilly And Co — how do they compare? VanEck Junior Gold Miners trades at $114.02 (market cap $8.22B), while Eli Lilly And Co trades at $1,177 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 126.5× VanEck Junior Gold Miners's market cap, and Eli Lilly And Co pays a 0.59% dividend while VanEck Junior Gold Miners pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and Eli Lilly And Co for 93 Days on average.
| GDXJ | LLY | |
|---|---|---|
Market Cap | $8.22B | $1.04T |
Volume | 3,212,198 | 3,064,878 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $1.28K |
52-Week Low | $87.56 | $799.57 |
Typical Hold Time | 41 Days | 93 Days |
Enterprise Value | — | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $113.02, up 3.56% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF is undergoing significant rebalancing, with multiple junior mining companies added in September 2026, potentially increasing diversification. Key support lies at $110, with resistance at $113. Financial ratios are not applicable as this is a fund tracking an index of gold mining equities.
The outlook remains cautious due to bearish technicals, though inclusion of new holdings may attract flows. Risks include gold price volatility and mining sector operational challenges. Analyst views on constituent stocks vary, but the ETF offers exposure to small-cap gold miners, which can be high-risk, high-reward during gold rallies.
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
